Constipation and other gut symptoms may show up years before the tremors, stiffness, or slowed movement commonly associated with Parkinson’s disease. That timing has helped make the gut-brain connection a major focus of Parkinson’s research. Scientists are investigating whether changes in gut bacteria and the substances they produce could influence processes involved in the disease—or whether those changes are mainly a consequence of Parkinson’s and its treatment.
What the New Research Found
A team from Nagoya University in Japan, led by Hiroshi Nishiwaki and Jun Ueyama, published a meta-analysis in npj Parkinson’s Disease on May 21, 2024. The researchers combined their own stool samples with data from five previously published datasets.
The Japanese study included 94 people with Parkinson’s disease and 73 controls. The additional datasets came from the United States, Germany, China, and Taiwan. Using this broader collection of information allowed the researchers to look for patterns that appeared across different countries rather than relying on one local population.
One of the clearest findings involved bacterial genes linked to the production of riboflavin, or vitamin B2, and biotin, or vitamin B7. These genes were significantly reduced in people with Parkinson’s disease across the countries included in the analysis.
That finding does not necessarily mean patients are simply deficient in B2 or B7. The study examined bacterial genes in stool, not whether an individual’s blood or tissues contained too little of either vitamin. It also does not prove that the changes caused Parkinson’s disease.
Why Gut Bacteria and B Vitamins Matter
Gut bacteria help produce or influence a wide range of substances. In this analysis, people with Parkinson’s also had lower levels of fecal short-chain fatty acids, commonly called SCFAs, and polyamines. These substances were correlated with the bacterial genes involved in riboflavin and biotin production.
SCFAs and polyamines are being studied because they may support the intestinal environment, including the mucus layer that helps protect the gut lining. The researchers propose that lower levels could weaken or thin that protective layer, potentially making the intestine more permeable.
A more permeable gut is one possible route through which abnormal immune activity or other biological signals might affect the nervous system. However, this remains a proposed mechanism, not an established explanation for Parkinson’s disease.
The findings also point to the possibility that gut bacteria may affect the body in ways that extend beyond digestion. Vitamin-related bacterial activity and the production of compounds such as SCFAs could be part of a larger network connecting the gut, immune system, and brain.
The Possible Link to Alpha-Synuclein
Parkinson’s disease is associated with abnormal accumulation of a protein called alpha-synuclein. The Nagoya University researchers suggest that a weakened mucus barrier and increased intestinal permeability could help promote abnormal alpha-synuclein aggregation in the gut’s nerve network.
They also discuss a possible connection to neuroinflammation, which refers broadly to inflammatory activity involving the nervous system. In this view, changes in the gut could contribute to biological signals that eventually affect the brain.
This idea is scientifically interesting, but it is not settled. The study was a meta-analysis of microbiome and related data, so it identified associations rather than proving a cause-and-effect chain. It remains uncertain whether gut changes begin the disease process, develop alongside it, or are influenced by other factors.
Which Bacteria Changed?
The analysis found several differences in particular bacterial species. Akkermansia muciniphila was increased in people with Parkinson’s disease, while Roseburia intestinalis and Faecalibacterium prausnitzii were decreased.
These findings should be interpreted carefully. A change in the amount of a particular bacterium does not automatically reveal whether it is harmful, protective, or simply responding to other changes in the gut. Bacteria can have different effects depending on the surrounding microbial community, diet, intestinal conditions, and the substances they produce.
The study’s most consistent signal involved bacterial genes for riboflavin and biotin production, along with lower SCFAs and polyamines. That pattern gives researchers specific areas to investigate, but it does not yet identify a proven microbiome-based treatment.
What This Means for B-Vitamin Supplements
The authors suggest that riboflavin or biotin supplementation might help a subset of people with Parkinson’s disease. Importantly, this is a hypothesis. No clinical trial has shown that B vitamins treat Parkinson’s disease or slow its progression.
A supplement also may not recreate the activity of a healthy gut ecosystem. The study focused on bacterial genes and stool-related compounds, so taking a vitamin does not necessarily correct every change observed in the microbiome. Whether supplementation could help, which patients might benefit, and what doses would be appropriate all require clinical research.
People with Parkinson’s should not change prescribed treatment or begin supplements for this purpose without discussing the decision with their neurologist. Supplements can have risks, interactions, or misleading claims even when the nutrient itself is familiar.
Why Constipation Deserves Attention
Gut symptoms, especially constipation, can occur years before motor symptoms of Parkinson’s disease. In some cases, such symptoms may appear 10 to 20 years beforehand. That does not mean constipation predicts Parkinson’s disease; it is common and can have many causes.
Still, the long interval between early gut symptoms and later motor changes makes the gut-brain axis an important research area. Scientists hope that understanding these early biological changes could eventually improve the ability to identify risk, distinguish disease subtypes, or develop new treatments.
For now, the strongest conclusion is more limited: Parkinson’s disease is associated with meaningful changes in gut microbial genes and gut-derived compounds, including pathways related to vitamins B2 and B7. The connection is promising, but it is not yet a proven treatment pathway.
Takeaway
Research on Parkinson’s gut bacteria suggests that reduced microbial genes for producing riboflavin and biotin may occur alongside lower SCFAs and polyamines. These changes could affect the intestinal barrier and may be linked to alpha-synuclein activity and inflammation, but the chain of events remains unproven. B-vitamin supplements are not established treatments, and patients should consult their neurologist before changing care.
Sources
– “Gut microbiota alterations in Parkinson’s disease: a meta-analysis” — npj Parkinson’s Disease
– Nagoya University research release
